Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 14/20 | 0.52 |
| ▸ | CTSB | P07858 | 3/20 | 0.52 |
| ▸ | CAPN9 | O14815 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | CTSH | P09668 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSC | P53634 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9089222 | 0.99 | CAPN1 (0.51) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL6929670 | 0.85 | CAPN1 (0.50) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL11067480 | 0.80 | CAPN1 (0.74) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL11184932 | 0.79 | CAPN1 (0.72) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL11188762 | 0.79 | CAPN1 (0.72) | CAPN1CTSBCAPN9MAPK1CTSL | |
| Hydrochloric Acid SCHEMBL9090223 | 0.78 | MC4R (0.45) | CAPN1 | |
| SCHEMBL15224395 | 0.77 | CHRND (0.40) | — | |
| SCHEMBL22392911 | 0.77 | CAPN1 (0.53) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL25314124 | 0.77 | CAPN1 (0.62) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL25314133 | 0.77 | CAPN1 (0.62) | CAPN1CTSBCAPN9MAPK1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961730-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XenoPort, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2015-06-11 | — | — | US | claimed |
| WO-2014134005-A2 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-09-04 | — | — | WO | claimed |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | XENOPORT, INC. (US) | 2014-08-28 | — | — | US | claimed |
| CN-101486668-B | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT INC | 2014-07-02 | — | — | CN | claimed |
| US-8299291-B2 | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs | XENOPORT, INC. (US) | 2012-10-30 | — | — | US | claimed |
| US-8062870-B2 | Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs | XENOPORT, INC. (US) | 2011-11-22 | — | — | US | claimed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| CN-112608307-B | Heterocyclic substituted 1,3,4-oxadiazole hydrazide compound as well as preparation method and application thereof | 贵州大学 | 2023-11-17 | — | — | CN | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11607458-B2 | Enrichment-triggered chemical delivery system | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-7511158-B2 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070244331-A1 | Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof | XENOPORT, INC. | 2007-10-18 | — | — | US | disclosed |
| US-7227028-B2 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20070037988-A9 | Formation of a thiocarbamate from a haloformic compound, dehalo-esterification, coupling an N-hydroxysuccinimide or secondary amide-containing drug; prodrugs of gabapentin and baclofen; improved bioavailability | XENOPORT, INC. | 2007-02-15 | — | — | US | disclosed |
| EP-1716115-A2 | SYNTHESIS OF ACYLOXYALKYL CARBAMATE PRODRUGS AND INTERMEDIATES THEREOF | Xenoport, Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050222431-A1 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XENOPORT, INC. | 2005-10-06 | — | — | US | disclosed |
| WO-2005066122-A2 | SYNTHESIS OF ACYLOXYALKYL CARBAMATE PRODRUGS AND INTERMEDIATES THEREOF | XENOPORT, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222431-A1 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | CPS1, ACMSD, NAAA | CAPN1 131/4885CTSB 642/4885CAPN9 277/4885 |
| US-11607458-B2 | Enrichment-triggered chemical delivery system | HMGB1, PAICS, CCL2 | CAPN1 659/4885CTSB 27/4885CAPN9 418/4885 |
| US-20150158809-A9 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | CAPN1 51/4885CTSB 317/4885CAPN9 55/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | CAPN1 1592/4885CTSB 1063/4885CAPN9 2963/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | CAPN1 2054/4885CTSB 77/4885CAPN9 1164/4885 |
| US-20140243544-A1 | METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS | CPS1, CA7, NAAA | CAPN1 51/4885CTSB 317/4885CAPN9 55/4885 |
| US-20070244331-A1 | Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof | CPS1, ACMSD, NAAA | CAPN1 131/4885CTSB 642/4885CAPN9 277/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | CAPN1 2054/4885CTSB 77/4885CAPN9 1164/4885 |
| US-20070037988-A9 | Formation of a thiocarbamate from a haloformic compound, dehalo-esterification, coupling an N-hydroxysuccinimide or secondary amide-containing drug; prodrugs of gabapentin and baclofen; improved bioavailability | SLC6A13, SLC6A11, SLC6A1 | CAPN1 582/4885CTSB 1664/4885CAPN9 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.